Genelux Corporation
Genelux Corporation
Your view on GNLX
Overview
What the company does, where it operates, and who runs it.
About Genelux Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas D. Zindrick
- Headquarters
- 2625 Townsgate Road, Westlake Village, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas D. Zindrick
- Headquarters
- 2625 Townsgate Road, Westlake Village, CA, US
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.